Curasight‘s experimental cancer therapy, uTREAT, has successfully reached its target in the brain of the first patient dosed in a Phase 1 clinical trial.
Glioma
Treatment with DeltEx DRI, a cell therapy developed by In8bio, is prolonging survival outcomes among people with newly diagnosed glioblastoma in a clinical…
TTX-MC138, an RNA-based therapy from Transcode Therapeutics that’s in early clinical development, induced tumor cell death and prolonged survival in a mouse model of…
The first participant has been dosed in an early clinical trial testing the experimental radiation therapy Alpha DaRT in people with hard-to-treat glioma. The…
Treatment with the experimental medication eflornithine in combination with the approved chemotherapy Gleostine (lomustine) may help improve survival in people with aggressive astrocytoma carrying IDH…
The U.S. Food and Drug Administration (FDA) has granted fast track status to zotiraciclib (ZTR/TG02) — an oral medication that targets pathways in the body…
Neonc Technologies has completed enrollment for its Phase 2a clinical trial of NEO100, an intranasal treatment for high-grade glioma, the company announced. This follows…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, a treatment candidate from Purdue Pharma that aims to extend…
Enrollment has begun in the second part of a clinical trial testing safusidenib, an experimental oral treatment, as a maintenance therapy for high-grade IDH1-mutant astrocytoma,…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to iopofosine I 131 — now being tested in young people in…
